Glucose utilization of four cerebral cortex and 35 subcortical regions
(CGU) was analyzed in three models of cholinergic seizures induced by
the following compounds: 1) soman (pinacolylmethylphosphonofluoridate
) an organophosphorus cholinesterase inhibitor, 100 mu g/kg SC after p
retreatment with pyridostigmine 26 mu g/kg IM (n = 6); 2) physostigmin
e, a carbamate cholinesterase inhibitor, 1.31 mg/kg infused IV over 75
min (n = 6); and 3) pilocarpine, a direct cholinergic agonist, 30 mg/
kg SC (n = 6), Physostigmine and pilocarpine were preceded by 3 mmol/k
g LiCl IP 20 hrs earlier, Animals injected with saline SC (n = 6) were
used as controls, Step-wise discriminant analysis successfully classi
fied 100% of the cases into the four experimental groups with data fro
m only six regions, Pyridostigmine-soman induced the most widespread a
nd greatest increases in CGU. More restricted and lower levels of acti
vation were observed with Li-pilocarpine while Li-physostigmine induce
d significant increases in CGU only in globus pallidus, entopeduncular
nucleus, and substantia nigra, These three regions, which are functio
nally related, were also activated in the other two models of choliner
gic convulsions and may represent the initial step in cholinergic acti
vation of the CNS, Li-pilocarpine failed to activate most of the brain
stem and the superior colliculus. All cortical regions were activated
by Li-pilocarpine and pyridostigmine-soman, while they were inhibited
by Li-physostigmine. This phenomenon may be due in part to the lack of
activation with physostigmine of the basal forebrain nuclei (lateral
septum, medial septum, vertical and horizontal limbs of the diagonal b
and, and substantia innominata) resulting in a decreased drive of cort
ical metabolism. (C) 1998 Elsevier Science Inc.